Jump to content

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab


In The News

Recommended Posts

Archived

This topic is now archived and is closed to further replies.



×
×
  • Create New...